Progress toward sustainable influenza vaccination in the Lao Peoples' Democratic Republic, 2012-2018.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
21 05 2019
Historique:
received: 14 12 2018
revised: 03 04 2019
accepted: 08 04 2019
pubmed: 28 4 2019
medline: 26 9 2020
entrez: 28 4 2019
Statut: ppublish

Résumé

Despite global recommendations for influenza vaccination of high-risk, target populations, few low and middle-income countries have national influenza vaccination programs. Between 2012 and 2017, Lao PDR planned and conducted a series of activities to develop its national influenza vaccine program as a part of its overall national immunization program. In this paper, we review the underlying strategic planning for this process, and outline the sequence of activities, research studies, partnerships, and policy decisions that were required to build Laos' influenza vaccine program. The successful development and sustainability of the program in Laos offers lessons for other low and middle-income countries interested in initiating or expanding influenza immunization.

Identifiants

pubmed: 31027926
pii: S0264-410X(19)30511-0
doi: 10.1016/j.vaccine.2019.04.047
pii:
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3002-3005

Informations de copyright

Published by Elsevier Ltd.

Auteurs

A Xeuatvongsa (A)

Ministry of Health, Vientiane, Laos.

J A Mott (JA)

Centers for Disease Control and Prevention, Bangkok, Thailand.

V Khanthamaly (V)

Centers for Disease Control and Prevention, Vientiane, Laos.

C Patthammavong (C)

Ministry of Health, Vientiane, Laos.

K Phounphenghak (K)

Ministry of Health, Vientiane, Laos.

M McKinlay (M)

Task Force for Global Health, Atlanta, GA, USA.

S Mirza (S)

Centers for Disease Control and Prevention, Atlanta GA, USA.

K E Lafond (KE)

Centers for Disease Control and Prevention, Atlanta GA, USA.

M McCarron (M)

Centers for Disease Control and Prevention, Atlanta GA, USA.

A Corwin (A)

Thammasat University, Faculty of Public Health, Bangkok, Thailand.

A Moen (A)

Centers for Disease Control and Prevention, Atlanta GA, USA.

S J Olsen (SJ)

Centers for Disease Control and Prevention, Atlanta GA, USA.

J S Bresee (JS)

Centers for Disease Control and Prevention, Atlanta GA, USA. Electronic address: jsb6@cdc.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH